Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice

Yu Lun Chuang, Hsu Wei Fang, Aditya Ajitsaria, Ko Hua Chen, Chen Ying Su, Guei Sheung Liu, Ching Li Tseng

研究成果: 雜誌貢獻文章

摘要

Cornea is the transparent layer in front of the eye that does not contain blood vessels. Among eye diseases, corneal neovascularization (NV) is one of the major causes of vision loss, since it can also lead to blindness. An herbal extraction containing flavonoid, kaempferol (KA), with antiangiogenic effect was chosen as a candidate drug for inhibited vessel formation. The use of nanomedicine has led to higher drug bioavailability and slow release of the drug as an effective therapeutic formulation in ocular drug delivery. In this study, we prepared gelatin nanoparticles (GNP) with kaempferol encapsulation (GNP-KA) for corneal NV treatment by topical delivery, i.e., eye drops. We found that GNP with/without KA loading was in the size of 85−150 nm, and its zeta potential was around 22−26 mV. The KA entrapment rate of GNP-KA was around 90−98%, and the loading rate was about 4.6%. The TEM results clearly indicated the GNP-KA NPs to be round spheres. The in vitro test involved the adoption of human umbilical vein endothelial cells (HUVECs) for coculture with these nanoparticles. From WST-8 assay, and cell migration examinations, it was evident that GNP-KA had the capacity to inhibit the cell viability and function of HUVECs. The results from in vivo tests such as ocular vessels observation, hematoxylin & eosin (H&E) stain, and metalloproteinases (MMP)/vascular endothelial growth factor (VEGF) quantification revealed the mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group by reducing the production of MMP and VEGF in the cornea. Therefore, we expected to achieve a comfortable treatment with a simple method using nanomedicine (GNP-KA) as ophthalmological agent delivered as eye drops.

原文英語
文章編號635
期刊Pharmaceutics
11
發行號12
DOIs
出版狀態已發佈 - 十二月 2019

指紋

Corneal Neovascularization
Gelatin
Nanoparticles
Ophthalmic Solutions
Therapeutics
Cornea
Nanomedicine
Human Umbilical Vein Endothelial Cells
Matrix Metalloproteinases
Vascular Endothelial Growth Factor A
kaempferol
Pharmaceutical Preparations
Eye Diseases
Metalloproteases
Therapeutic Uses
Blindness
Hematoxylin
Eosine Yellowish-(YS)
Coculture Techniques
Flavonoids

ASJC Scopus subject areas

  • Pharmaceutical Science

引用此文

Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice. / Chuang, Yu Lun; Fang, Hsu Wei; Ajitsaria, Aditya; Chen, Ko Hua; Su, Chen Ying; Liu, Guei Sheung; Tseng, Ching Li.

於: Pharmaceutics, 卷 11, 編號 12, 635, 12.2019.

研究成果: 雜誌貢獻文章

Chuang, Yu Lun ; Fang, Hsu Wei ; Ajitsaria, Aditya ; Chen, Ko Hua ; Su, Chen Ying ; Liu, Guei Sheung ; Tseng, Ching Li. / Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice. 於: Pharmaceutics. 2019 ; 卷 11, 編號 12.
@article{6bf6680f6d714fa38a4c8926dfa2d121,
title = "Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice",
abstract = "Cornea is the transparent layer in front of the eye that does not contain blood vessels. Among eye diseases, corneal neovascularization (NV) is one of the major causes of vision loss, since it can also lead to blindness. An herbal extraction containing flavonoid, kaempferol (KA), with antiangiogenic effect was chosen as a candidate drug for inhibited vessel formation. The use of nanomedicine has led to higher drug bioavailability and slow release of the drug as an effective therapeutic formulation in ocular drug delivery. In this study, we prepared gelatin nanoparticles (GNP) with kaempferol encapsulation (GNP-KA) for corneal NV treatment by topical delivery, i.e., eye drops. We found that GNP with/without KA loading was in the size of 85−150 nm, and its zeta potential was around 22−26 mV. The KA entrapment rate of GNP-KA was around 90−98{\%}, and the loading rate was about 4.6{\%}. The TEM results clearly indicated the GNP-KA NPs to be round spheres. The in vitro test involved the adoption of human umbilical vein endothelial cells (HUVECs) for coculture with these nanoparticles. From WST-8 assay, and cell migration examinations, it was evident that GNP-KA had the capacity to inhibit the cell viability and function of HUVECs. The results from in vivo tests such as ocular vessels observation, hematoxylin & eosin (H&E) stain, and metalloproteinases (MMP)/vascular endothelial growth factor (VEGF) quantification revealed the mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group by reducing the production of MMP and VEGF in the cornea. Therefore, we expected to achieve a comfortable treatment with a simple method using nanomedicine (GNP-KA) as ophthalmological agent delivered as eye drops.",
keywords = "Anti-angiogenesis, Corneal neovascularization, Gelatin nanoparticles, Human umbilical vascular endothelial cells (HUVECs), Kaempferol",
author = "Chuang, {Yu Lun} and Fang, {Hsu Wei} and Aditya Ajitsaria and Chen, {Ko Hua} and Su, {Chen Ying} and Liu, {Guei Sheung} and Tseng, {Ching Li}",
year = "2019",
month = "12",
doi = "10.3390/pharmaceutics11120635",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1999-4923",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

TY - JOUR

T1 - Development of Kaempferol-loaded gelatin nanoparticles for the treatment of corneal neovascularization in mice

AU - Chuang, Yu Lun

AU - Fang, Hsu Wei

AU - Ajitsaria, Aditya

AU - Chen, Ko Hua

AU - Su, Chen Ying

AU - Liu, Guei Sheung

AU - Tseng, Ching Li

PY - 2019/12

Y1 - 2019/12

N2 - Cornea is the transparent layer in front of the eye that does not contain blood vessels. Among eye diseases, corneal neovascularization (NV) is one of the major causes of vision loss, since it can also lead to blindness. An herbal extraction containing flavonoid, kaempferol (KA), with antiangiogenic effect was chosen as a candidate drug for inhibited vessel formation. The use of nanomedicine has led to higher drug bioavailability and slow release of the drug as an effective therapeutic formulation in ocular drug delivery. In this study, we prepared gelatin nanoparticles (GNP) with kaempferol encapsulation (GNP-KA) for corneal NV treatment by topical delivery, i.e., eye drops. We found that GNP with/without KA loading was in the size of 85−150 nm, and its zeta potential was around 22−26 mV. The KA entrapment rate of GNP-KA was around 90−98%, and the loading rate was about 4.6%. The TEM results clearly indicated the GNP-KA NPs to be round spheres. The in vitro test involved the adoption of human umbilical vein endothelial cells (HUVECs) for coculture with these nanoparticles. From WST-8 assay, and cell migration examinations, it was evident that GNP-KA had the capacity to inhibit the cell viability and function of HUVECs. The results from in vivo tests such as ocular vessels observation, hematoxylin & eosin (H&E) stain, and metalloproteinases (MMP)/vascular endothelial growth factor (VEGF) quantification revealed the mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group by reducing the production of MMP and VEGF in the cornea. Therefore, we expected to achieve a comfortable treatment with a simple method using nanomedicine (GNP-KA) as ophthalmological agent delivered as eye drops.

AB - Cornea is the transparent layer in front of the eye that does not contain blood vessels. Among eye diseases, corneal neovascularization (NV) is one of the major causes of vision loss, since it can also lead to blindness. An herbal extraction containing flavonoid, kaempferol (KA), with antiangiogenic effect was chosen as a candidate drug for inhibited vessel formation. The use of nanomedicine has led to higher drug bioavailability and slow release of the drug as an effective therapeutic formulation in ocular drug delivery. In this study, we prepared gelatin nanoparticles (GNP) with kaempferol encapsulation (GNP-KA) for corneal NV treatment by topical delivery, i.e., eye drops. We found that GNP with/without KA loading was in the size of 85−150 nm, and its zeta potential was around 22−26 mV. The KA entrapment rate of GNP-KA was around 90−98%, and the loading rate was about 4.6%. The TEM results clearly indicated the GNP-KA NPs to be round spheres. The in vitro test involved the adoption of human umbilical vein endothelial cells (HUVECs) for coculture with these nanoparticles. From WST-8 assay, and cell migration examinations, it was evident that GNP-KA had the capacity to inhibit the cell viability and function of HUVECs. The results from in vivo tests such as ocular vessels observation, hematoxylin & eosin (H&E) stain, and metalloproteinases (MMP)/vascular endothelial growth factor (VEGF) quantification revealed the mice’s eyes with corneal NV treated by eye drops containing GNP-KA once daily for 7 days had better therapeutic effects with less vessels in-growths in the cornea, compared to the KA solution group by reducing the production of MMP and VEGF in the cornea. Therefore, we expected to achieve a comfortable treatment with a simple method using nanomedicine (GNP-KA) as ophthalmological agent delivered as eye drops.

KW - Anti-angiogenesis

KW - Corneal neovascularization

KW - Gelatin nanoparticles

KW - Human umbilical vascular endothelial cells (HUVECs)

KW - Kaempferol

UR - http://www.scopus.com/inward/record.url?scp=85075873492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075873492&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics11120635

DO - 10.3390/pharmaceutics11120635

M3 - Article

AN - SCOPUS:85075873492

VL - 11

JO - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 12

M1 - 635

ER -